RE: Cepi13 May 2021 03:55
Wildforce, thanks for your post 18.36 a very interesting article, well worth the read. Having problems copy and pasting at the moment, hopefully this works..........................
Making ‘variant-proof’ vaccines of the future
With the potential for variants to evade our vital pandemic-ending tools, CEPI, in addition to its monitoring and vaccine analysis work, is therefore staying one step ahead through directly funding further research and development of COVID-19 vaccines tailored to target variants of concern.
In March 2021, we announced that we would provide up to $33m in funding to VBI Vaccines to develop their enveloped virus like particle (eVLP) vaccine candidate through Phase I clinical development against SARS-CoV-2 variants, including the B.1.351 variant. In addition, CEPI is also investing up to $14.2m in SK Bioscience’s recombinant protein vaccine candidate to support its adaptation against variants of concern. Further funding is advancing SK Bioscience’s manufacturing methods to enable the potential production of hundreds of millions of doses of its candidate vaccine.
If both vaccines are successful, VBI and SK bioscience have agreed that the vaccines supported by CEPI will be made available to COVAX for allocation to vulnerable populations worldwide. The shots could be used to increase initial supplies of vaccines and/or as potential booster doses.
Considering the threat of additional variants and potential future outbreaks caused by other coronaviruses, CEPI has also announced that it will provide up to $200m to vaccine developers to advance work to move away from the traditional “one bug, one drug” approach and create an all-encompassing broadly-protective coronavirus shot. Open worldwide to research and development organisations with expertise in vaccine development, CEPI plans to invest in promising multi-coronavirus vaccine candidates up to clinical proof-of-concept.
While an incredibly challenging area of work, a broadly protective coronavirus vaccine could provide significant benefits, through potentially helping to avert another COVID-19-like pandemic, minimising the need to continually update vaccine components, and ultimately reducing virus circulation.
The work forms part of CEPI’s long-term $3.5bn investment strategy, announced in March, 2021, to tackle the imminent threat of COVID-19, while also advancing the innovative tools and networks to reduce or even mitigate future pandemics and epidemics.
AS i say the whole article is worth a read, and the more I read it seems inconceivable that we will not get any funding from CEPI. That is IMHO.
Thanks Bermuda too, great research and a hearty thanks for finding so much information, as applies to cc, as ever as well.
""We will be in 3 trials within months""is what I was told and any talks with CEPI, UK.Government and any other partners should be at a very advanced state now, and it raises my hopes that we will be hearing the first news very soon.
Sign In
Follow the stocks
